Pfizer investigates safety of experimental drug in healthy people
NCT ID NCT06659250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and how the body handles a new drug called PF-06414300 in 63 healthy adults. Participants received either the drug or a placebo in single or multiple doses. The study is complete and focused on measuring side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-06414300
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mind over movement: can imagining exercise boost balance and brainpower?
- Can a cancer drug be tailored for japanese patients? a new trial seeks answers
- Which pill works best? a trial puts elecoglipron formulations to the test
- Vitamin c may shield postmenopausal hearts without hormones
- Inhaled experimental drug targets tough lung infections
- Meal timing and stomach acid drugs may change how this experimental drug works